The Spanish blood management company was founded in 1940 in Barceloby Dr. José Grifols Roig, a hematologist and scientist, who was the first researcher to publish the plasmapheresis procedure in 1951. In June 2011, Grifols closed the $4 billion buyout of Talecris Biotherapeutics; in 2013 it acquired the Novartis blood transfusion diagnostics unit.

Grifols agrees to acquire a 517,000 sq ft plot of land to expand its production facilities in Barcelona, Spain. FDA Approves Use of the Procleix Zika Virus Assay from Hologic and Grifols to Screen the U.S. Blood Supply Under an IND Study Protocol. Grifols confirms that it has voluntarily signed the EFPIA Code of Conduct. Grifols will invest USD 360M to expand its manufacturing capacities for plasma-derived therapies. Grifols invests in the project led by AlbaJuna Therapeutics, a spin-off from IrsiCaixa, to fund the development of therapeutic antibodies against HIV. Grifols Obtains Exclusive Rights to Market and Distribute MassBiologics’ Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine in U.S. Grifols agrees long term loan with the European Investment Bank. Grifols official opening of the Bioscience Division new worldwide operations facility in Ireland. Grifols to make a major equity investment in Alkahest. Grifols PhocusRx Certified DIACAP Compliant. Grifols partners with Johnston County educators to develop science program. Grifols receives FDA approval for its new purification plant to produce Gamunex in Los Angeles.